证券代码：300138 证券简称：晨光生物 编号：2023-006 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类 别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 √其他 （电话会议） 东方证券彭博、中金公司宗旭豪、长江证券陈硕旸、嘉实 基金吴悠、中信保诚基金陈超俊、宝盈基金张若伦、博时 参与单位名称及人 基金卓若伟、兴业基金姜涵予、中欧基金寇煜、东海基金 员姓名 杨恒、华夏久盈李晓杰、中邮人寿保险高远、华泰资管董 懿夫、景林资产雨晨、森锦投资黄裕金等 151 名投资者。 时间 2023 年 8 月 14 日 地点 河北省邯郸市曲周县城晨光路 1 号会议室 其他各电话会议方处不同地点 上市公司接待人员 董办主任门宁 一、公司上半年经营情况介绍 二、投资者提问与回答 1、目前辣椒红的价格处于历史什么水平？新疆辣椒减 产对辣椒红利润有什么影响？ 受 5 月新疆异常气候影响，预计今年新疆辣椒将会减 投资者关系活动主 产，新一季辣椒采购价格有可能会上涨。公司采用成本加 要内容介绍 成的定价方式，产品销售价格将根据采购成本确定，新疆 辣椒减产对辣椒红利润影响较小。受原材料涨价预期影响， ...

Financial Performance - In the first half of 2023, the company achieved operating revenue of 3.669 billion CNY, a year-on-year increase of 24.23% [2] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 236 million CNY, with non-recurring gains and losses amounting to 62.87 million CNY, up 339.5% year-on-year [2] - The overall profit growth rate is consistent after excluding the impact of non-recurring gains and losses [2] Product Performance - The gross margin for natural pigments/spices/nutritional and medicinal products was 20.93%, a decrease of 2.39% year-on-year, primarily due to low prices of lutein [3] - Sales of chili red pigment reached approximately 5,900 tons, a year-on-year increase of about 16%, with chili extract prices remaining high [3] - Sales of feed-grade lutein decreased by about 70%, while food-grade lutein sales increased by over 110% [3] New Business Development - The health food business achieved sales revenue of over 70 million CNY, a year-on-year growth of over 60% [4] - The company is expanding its raw material base, with significant growth in planting areas for marigold in India and Zambia [4] - The cottonseed protein business maintained steady operations, effectively mitigating risks from market fluctuations [4] Investment and Capacity Expansion - The company is focusing on three major projects: a cottonseed processing project with a capacity of 350,000 tons, a marigold extraction production line in Zambia, and a comprehensive extraction project for turmeric and silymarin [5] - The company plans to expand its planting area in Zambia and improve production line construction based on planting conditions [4] Market and Pricing Strategy - The fluctuation in lutein prices is significantly influenced by the agricultural cycle of marigold, leading to price volatility [5] - The company is implementing pre-sale strategies to stabilize planting expectations and mitigate price fluctuations in the lutein market [5] - The demand for feed-grade lutein is growing at a low single-digit rate annually, with sales adjustments made to control market supply [5]

特此公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（简称"公司"）于 2022 年 8 月 21 日召开 了第四届董事会第四十四次会议，审议通过了《关于注销子公司的议案》，同意 注销子公司——叶城县晨龙生物科技有限公司（简称"叶城晨龙"），详细内容 请参见 2022 年 8 月 23 日披露于巨潮资讯网的相关公告。 近日，公司收到叶城县市场监督管理局出具的《登记通知书》，叶城晨龙已 按照相关程序完成了企业注销登记手续。本次注销完成后，公司合并报表范围将 相应发生变化，叶城晨龙将不再纳入公司合并报表范围。 叶城晨龙的注销，不会对公司的财务及经营状况产生重大影响，不存在损害 公司及股东利益的情形。 证券代码：300138 证券简称：晨光生物 公告编号：2023—111 晨光生物科技集团股份有限公司 关于子公司注销完成的公告 晨光生物科技集团股份有限公司 董事会 2023年8月15日 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—110 晨光生物科技集团股份有限公司 关于变更部分募集资金用途的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 董事会 2023年8月15日 晨光生物科技集团股份有限公司（以下简称"公司"）第四届董事会第五十 次会议、第四届监事会第三十四次会议、2023 年第一次临时股东大会审议通过 了《关于变更募集资金用途的议案》。根据公司长期战略规划，结合现阶段发展 需求，为提高募集资金使用效率、优化资源配置，公司决定变更可转债部分募集 资金用途，将用于"天然植物综合提取一体化项目（一期）"的部分募集资金 6,500 万元变更用于"营养药用综合提取项目（一期）"，详细内容请参见公司 2023 年 5 月 13 日及 5 月 29 日披露于巨潮资讯网的相关公告。 2023 年 7 月 12 日，公司与保荐机构中原证券股份有限公司、中国农业银行 股份有限公司曲周县支行（以下简称"农行曲周县支行"）签订了《募集资金三 方监管协议》，并已在农行曲周县支行设立了募集资金专项账户。2023 年 7 月 13 日 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—109 晨光生物科技集团股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）于 2022 年 9 月 22 日召开的第四届董事会第四十五次会议审议通过了《关于使用部分闲置募集资金 进行现金管理的议案》。同意公司在不影响募集资金投资项目建设的前提下，使 用不超过 2.75 亿元暂时闲置募集资金进行现金管理，用于购买安全性高、流动 性好的理财产品/结构性存款产品等，期限为自董事会审议通过之日起不超过 12 个月，期限内在上述资金额度范围内滚动使用，到期前将归还至公司募集资金专 户。公司独立董事、监事会、保荐机构已发表明确同意意见，详细内容请见 2022 年 9 月 22 日披露于巨潮资讯网的《关于使用部分闲置募集资金进行现金管理的 公告》及相关公告文件。 前期，公司使用暂时闲置募集资金 3,000 万元购买了江海证券有限公司收益 凭证（详细内容请见 2022 年 11 月 10 日披露于巨潮资讯网 ...

一、保荐机构进行的核查工作 报告期内，本保荐机构对晨光生物募集资金的存放、使用及募集资金投资项 目实施情况进行了核查，主要内容包括：与公司相关董事、监事、高级管理人员、 内部审计人员、注册会计师等人员交谈，查询了募集资金专户银行对账单，半年 度募集资金存放与使用情况的专项报告以及各项业务和管理规章制度，查阅募集 资金使用凭证，从公司募集资金的日常管理、使用用途、信息披露等方面对其募 集资金制度的完整性、合理性及有效性进行核查。 二、募集资金基本情况 经中国证券监督管理委员会《关于核准晨光生物科技集团股份有限公司公开 发行可转换公司债券的批复》（证监许可[2019]2571号）核准，同意晨光生物向 社会公开发行面值总额63,000万元的可转换公司债券，期限6年。本次发行可转 换公司债券的募集资金总额为人民币63,000万元，扣除发行费用1,095.57万元后， 晨光生物实际募集资金净额为61,904.43万元。上述募集资金于2020年6月23日到 位，已由中审众环会计师事务所审验并出具众环验字[2020]第020023号《验资报 告》。 中原证券股份有限公司 关于晨光生物科技集团股份有限公司 2023 年半年度 ...

控股股东及其他关联方非经营性资金占用及清偿情况表(2023年上半年度） 单位：晨光生物科技集团股份有限公司 | 控股股东或其他 | 占用时间 | 发生原因 | 期初余额 | 报告期新增 | 报告期偿还 | 期末余额 | 截至半年报 | 预计 | 预计 | 预计 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 关联方名称 | | | | 占用金额 | 总金额 | | 披露日余额 | 偿还方式 | 偿还金额 | 偿还时间 | | | | 河北晨华共两名股东，分别为晨光生物、华 裕永诚。为支持河北晨华业务发展，河北晨 | | | | | | | | 2023年4月完成 | | 河北晨华农业科 | | 华的两名股东决定按持股比例、同等条件分 | | | | | | | | 借款本金偿 | | 技有限公司 | 本报告期 | 别向其提供不超过3,000万元的资金支持，期 | 2,536.25 - - | 29.59 | 2,565.84 | | | 现金清偿 | - | 还，5月完成剩 | | | | 限为自签订的协议生效之日 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥3,668,696,988.23, representing a 13.68% increase compared to ¥3,227,191,537.69 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥298,654,394.22, an increase of 24.23% from ¥240,397,801.18 year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥235,787,929.76, up 11.49% from ¥211,485,971.37 in the previous year[22]. - The basic earnings per share increased to ¥0.56, a rise of 24.44% compared to ¥0.45 in the same period last year[22]. - The total assets at the end of the reporting period were ¥7,239,852,514.36, reflecting a 4.57% increase from ¥6,923,739,569.28 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were ¥3,397,025,349.56, which is a 7.34% increase from ¥3,164,817,273.47 at the end of the previous year[22]. - The net cash flow from operating activities was ¥682,564,463.95, down 29.19% from ¥963,901,233.43 in the same period last year[22]. - The weighted average return on net assets was 9.02%, an increase of 0.73% from 8.29% in the previous year[22]. - The company achieved a revenue of 3.669 billion yuan in the first half of 2023, representing a year-on-year growth of 13.68%[44]. - The net profit attributable to shareholders reached 299 million yuan, an increase of 24.23% compared to the previous year[44]. Market and Industry Insights - The global market for plant extracts is projected to reach USD 59.4 billion by 2025, indicating significant growth potential in the industry[31]. - The plant extraction industry in China has over 2,000 companies, with a trend towards consolidation and a focus on quality and technology-driven competition[34]. - The natural plant extract industry is driven by the long-term trend of replacing synthetic products, with applications in food, medicine, and cosmetics, indicating a broad market outlook[36]. - The global natural food coloring market is expected to reach $2.5 billion by 2025, driven by safety concerns over synthetic colors[37]. - The compound seasoning market in China grew from 43.2 billion yuan in 2011 to 144 billion yuan in 2020, with a CAGR of 14.31%[37]. - The penetration rate of pepper extract in the restaurant industry is currently below 2%, indicating significant growth potential[39]. - The demand for natural sweeteners is increasing as consumers shift towards low-sugar and no-sugar consumption concepts, with steviol glycosides being a key natural sweetener[40]. - Natural plant extracts are becoming essential raw materials in pharmaceuticals, health products, and cosmetics, with a positive development outlook[40]. Product Development and R&D - The company employs a market-oriented R&D model that includes stages from small trials to industrial production, ensuring alignment with market needs[34]. - The company has developed over 100 varieties across six major series, including natural pigments and health food products[43]. - The company has invested significantly in R&D, focusing on process technology improvements and new product development[42]. - The company is currently developing a new process for pepper extract with a focus on low cost and high yield, and is in the process of scaling up the new technology[48]. - The company is working on the development of microencapsulated products to broaden its product range, with ongoing pilot tests and production trials[48]. - The company has achieved breakthroughs in the extraction of flavonoids from locust tree seeds, improving the efficiency of rutin acquisition and addressing traditional water consumption issues[49]. - The company has completed the verification of raw materials from different origins for locust tree seed products, enabling the production transformation of solvent extraction technology[49]. - The company has launched several new products, including various health supplements and soft capsules, to diversify its offerings[50]. Strategic Goals and Expansion - The company emphasizes the importance of global resource allocation to achieve its strategic goal of building a world-class natural extract industry base[3]. - The company is actively expanding its raw material bases, with significant growth in planting areas in India and Zambia[46]. - Morning Glory Bio has become the largest listed company in the domestic plant extract industry, ranking among the top tier globally, aiming to surpass foreign leaders like Frutarom and Kalsec[35]. - The company aims to establish around ten world-leading products in the near future[44]. - The company is expanding its operations internationally, with factories being established in India and Zambia as part of the Belt and Road Initiative[145]. Environmental and Social Responsibility - The company is committed to addressing environmental concerns through innovative extraction processes in its product development[49]. - The company has established a comprehensive wastewater treatment system to manage chemical pollutants effectively[142]. - The company has reported a significant investment in environmental protection equipment, including dust collectors and odor removal towers, to comply with environmental regulations[145]. - The company has actively participated in social welfare activities, contributing approximately 1 million rupees to local public services in India[146]. - The company has implemented measures to control emissions of nitrogen oxides, with a maximum allowable concentration of ≤80 mg/m³[139]. Corporate Governance and Shareholder Engagement - The company held an annual general meeting on April 19, 2023, with 31.52% of investors participating, approving various proposals including the 2022 annual report and financial statements[130]. - The company conducted investor communications through various platforms, including a conference call on March 28, 2023, attended by 210 investors[127]. - The company is focused on maintaining transparency and engaging with investors through regular updates and meetings[127]. - The company has not reported any significant mergers or acquisitions during the reporting period[132]. - The company confirmed that all commitments made by major shareholders have been fulfilled as of the report date[150]. Risk Management - The company has identified several risks associated with derivative investments, including market risk, basis risk, liquidity risk, operational risk, technical risk, and policy risk[114]. - The company has established a risk control framework to manage and mitigate the identified risks effectively[114]. - The company is monitoring foreign exchange risks as international revenues grow, utilizing financial tools to mitigate potential impacts[125]. Related Party Transactions - The company engaged in related party transactions, with a total transaction amount of 28.65 million yuan, accounting for 12.83% of similar transactions[165]. - The company confirmed that all related party transactions have not exceeded the approved limits as of the reporting period[168]. Financial Support and Guarantees - The company provided financial support of up to 30 million yuan to Hebei Chenhua, with a repayment period not exceeding 12 months, approved in the 2021 annual general meeting[155]. - The total approved guarantee amount for subsidiaries during the reporting period is CNY 310 million, with actual guarantees amounting to CNY 66.424 million[185]. - The company has no guarantees provided for shareholders, actual controllers, or their related parties[186].

证券代码：300138 证券简称：晨光生物 公告编号：2023—104 晨光生物科技集团股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、 审议通过了《关于<募集资金 2023 年半年度存放与使用情况的专项报告> 的议案》 表决结果：同意六票；反对零票；弃权零票。 报告具体内容、独立董事、监事会、保荐机构发表的意见，详见巨潮资讯网同 期披露的相关文件。 特此公告 晨光生物科技集团股份有限公司 董事会 2023 年 8 月 11 日 晨光生物科技集团股份有限公司（以下简称"公司"）董事会于 2023 年 7 月 27 日以专人送达、邮件方式向全体董事发出第五届董事会第二次会议通知，会议于 2023 年 8 月 10 日在公司会议室以现场与通讯相结合的方式召开。本次会议由董事长卢庆 国先生主持，应出席会议董事六人，实际出席会议董事六人（独立董事戴小枫、牛 翃、厉梁秋，董事卢颖以通讯表决方式参加），公司监事、高级管理人员列席了本 次会议。本次会议召开符合《公司法》《公司章程》等有关规定。经与会董事研究、 讨论，审议通过 ...

上市公司2023年上半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：晨光生物科技集团股份有限公司 金额单位：人民币万元 | | | 占用方与上市公司的关联 | 上市公司核算的 | 2023年初占用 | 2023年上半年度占 | 2023年上半年度占 | 2023年上半年度偿 | 2023年6月末占 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 关系 | 会计科目 | 资金余额 | 用累计发生金额（不 | 用资金的利息（如 | 还累计发生额 | 用资金余额 | 占用形成原因 | 占用性质 | | | | | | | 含利息） | 有） | | | | | | 控股股东、实际控制人及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小 计 | —— | —— | —— | - | - | - | - | - | —— | —— | | 前控股股东、实际控制人 | | | | | | | | | ...